A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Inclusion Criteria: * Have Crohn's Disease (CD) or fistulizing CD of at least 3 months duration (defined as a minimum of 12 weeks), with colitis, ileitis, or ileocolitis, confirmed at any time in the past by radiography, histology, and/or endoscopy * Have moderate to severe CD as assessed by CDAI components of stool frequency (SF), and abdominal pain (AP) scores, and endoscopic evidence * Have screening laboratory test results within the protocol specified parameters * A female participant of childbearing potential must have a negative urine pregnancy test result at screening and baseline * Demonstrated intolerance or inadequate response to conventional or to biologic therapy for CD Exclusion Criteria: * Has complications of CD, such as symptomatic strictures or stenoses, short gut syndrome, or any other manifestation * Unstable doses of concomitant Crohn's disease therapy * Receipt of Crohn's disease approved biologic agents, investigational agents, or procedures outside of permitted time frame as specified in the protocol * Prior exposure to p40 inhibitors or p19 inhibitors * Any medical contraindications preventing study participation